Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Insight - MicroRNA discoveries have huge implications

This article was originally published in Scrip

Executive Summary

There was a time when the Human Genome Project seemed likely to deliver every specific target the drug industry would ever need, and specific drug targeting was deemed the best way forward. Certainly it yielded data on hundreds of hitherto unknown proteins, ripe for investigation as therapeutic targets – but it now appears that this was actually far from being the end of the story. Hidden among the previously unfashionable realm of "non-coding" sequences lay what many believe are the true master-regulators of biological systems, opening up a whole new area for pharmaceutical R&D and one that seriously challenges our preconceptions regarding the specificity of drug targeting.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts